6Grerald K, Rudiger N, Constantin H, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled,double-blind study[J]. Hepatology, 1997,25(6) : 1351 - 1360.
7Larsen FS, Adel HB, Pott F, et al. Dissociated cerebral vasoparalysis in acute liver failure. A hypothesis of gradual cerebral hyperaemia. J Hepatol, 1996, 25: 145-151.
8Adawi D, Kasravi FB, Molin G, et al. Effect of Lactobacillus supplementation with and without arginine on liver damage and bacterial translocation in an acute liver injury model in the rat. Hepatology, 1997, 25: 642-647.
9Uribe M, Moran S, Poo JL, et al. Beneficial effect of carbohydrate maldigestion induced by a disaccharide inhibitor (AO-128) in the treatment of chronic portal-system encephalopathy. A double-blind, randomized, controlled trial. Scand J Gastroenterol, 1998, 33:1099-1106.
10Miglio F, Valpiani D, Rossellini SR, et al. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomized trial. Curr Med Res Opin, 1997, 13: 593-601.
4TROTTER J F, BRIMHALL B, ARJAL R, et al. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scares for patients listed for liver transplantation [ J ]. Liver Transp1,2004,10 ( 8 ) :995 - 1000.
5KIRCHEIS G, WETISTEIN M, DAHL S V, et al. Clinical efficacy of L-omithine-L-aspartate in the management of hepatic encephalopathy [J]. Metab Brain Dis,2002,17(4 ) :453 -462.
